logo

For the Inventor, By the Inventor

Tokyo, Japan

Chugai Seiyaku Kabushiki Kaisha


USPTO Granted Patents = 950



Trademarks = 12

Forward Citations = 8,859

Loading Chart...
Loading Chart...

1,288 inventors (with patents filed for the assignee):

goldMedal Tomoyuki Igawa (102 out of 102 patents)

silverMedal Masayuki Tsuchiya (42 out of 49 patents)

bronzeMedal Hiroyuki Tsunoda (29 out of 29 patents)

4.  Atsuhiko Maeda (26 out of 26 patents)

5.  Taichi Kuramochi (26 out of 26 patents)

6.  Takashi Emura (26 out of 26 patents)

7.  Toshihiko Ohtomo (25 out of 26 patents)

8.  Masahiro Nishimoto (21 out of 21 patents)

9.  Isao Matsunaga (21 out of 22 patents)

10.  Minoru Shindo (21 out of 22 patents)

11.  Naoka Hironiwa (20 out of 20 patents)

12.  Hirotake Shiraiwa (19 out of 19 patents)

13.  Tatsuhiko Tachibana (19 out of 19 patents)

14.  Shojiro Kadono (17 out of 17 patents)

15.  Hidetomo Kitamura (16 out of 17 patents)


Core Competencies:
Antibody-Containing Preparation
Pharmaceutical Formulation
Anti-CTLA-4 Antibody
Atopic Dermatitis Treatment
Nrf2 Activation Compounds
Antigen-Binding Molecules
GLP-1 Receptor Agonists
Cyclic Peptide Compounds
Bispecific Antibodies
Modified Fc Region
Anti-Myostatin Antibodies
Polypeptide Hetero-Oligomers

950 patents:

1. 12509524 - Antigen-binding molecule comprising altered antibody variable region (2025-12-30),
2. 12504275 - Parts supply device and parts transfer system (2025-12-23),
3. 12493033 - Method for detecting bi-specific antibody complex (2025-12-09),
4. 12460015 - Pharmaceutical formulation comprising aqueous solution of antibody (2025-11-04),
5. 12460014 - Antibody-containing preparation (2025-11-04),
6. 12448451 - Anti-CTLA-4 antibody and use thereof (2025-10-21),
7. 12441804 - Pharmaceutical composition for prevention and/or treatment of atopic dermatitis comprising IL-31 antagonist as active ingredient (2025-10-14),
8. 12441735 - Nitrogen-containing heterocyclic compound having NRF2 activation effect (2025-10-14),
9. 12435147 - Nemolizumab in the treatment of atopic dermatitis with moderate to severe excoriation (2025-10-07),
10. 12435137 - Antigen-binding molecule containing two antigen-binding domains that are linked to each other (2025-10-07),
11. 12428496 - Antibodies, compositions for use in detecting or capturing a polypeptide in a sample, and methods for detecting or capturing a polypeptide in a sample (2025-09-30),
12. 12421322 - Antibody variant and isoform with lowered biological activity (2025-09-23),
13. 12415857 - Anti-CTLA-4 antibody and use thereof (2025-09-16),
14. 12415835 - Peptide-compound cyclization method (2025-09-16),
15. 12410212 - Cyclic compound having selective KRAS inhibitory effect on HRAS and NRAS (2025-09-09),
Chugai Seiyaku Kabushiki Kaisha is a leading Japanese pharmaceutical company engaged in the research, development, manufacturing, and marketing of innovative pharmaceutical products. With a focus on oncology and specialty care, Chugai strives to create advanced medicinal solutions to address unmet medical needs. Their dedication to improving patient outcomes and quality of life has made them a trusted name in the healthcare industry.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Jan 6 2026

...
950 Patents

#105 in Tokyo

#231 in Japan

#1,043 in the World

...
Tokyo, Japan

Chugai Seiyaku Kabushiki Kaisha

Forward Citations = 8,859

1,288 inventors:

goldMedal Tomoyuki Igawa (102 out of 102 patents)

silverMedal Masayuki Tsuchiya (42 out of 49 patents)

bronzeMedal Hiroyuki Tsunoda (29 out of 29 patents)

4.  Atsuhiko Maeda (26 out of 26 patents)

5.  Taichi Kuramochi (26 out of 26 patents)

Please report any incorrect information to support@idiyas.com
Loading…